The brightest stars of Broadway will perform electrifying show tunes in the Pulmonary Fibrosis Foundation's (PFF) 15th annual ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...

Researchers assessed the effect of long-term air pollution exposure on disease severity and progression in patients with idiopathic pulmonary fibrosis.

Research highlights gender-based disparities in lung transplantation, showing women face longer wait times yet achieve better ...

2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by progressive scarring of the lungs, leading to respiratory failure and death. Therapies to treat IPF are ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

Inhibiting the HIF2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these ...